Compare PAYP & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | CYTK |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 10.7B |
| IPO Year | 2025 | 2004 |
| Metric | PAYP | CYTK |
|---|---|---|
| Price | $14.95 | $74.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $25.54 | ★ $89.26 |
| AVG Volume (30 Days) | 898.3K | ★ 1.8M |
| Earning Date | 08-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | $20.92 | $310.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.07 | $35.22 |
| 52 Week High | $24.89 | $88.31 |
| Indicator | PAYP | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 39.47 |
| Support Level | $14.72 | $73.95 |
| Resistance Level | $16.56 | $80.65 |
| Average True Range (ATR) | 0.80 | 2.97 |
| MACD | -0.10 | -0.67 |
| Stochastic Oscillator | 18.41 | 18.84 |
PayPay Corp is a FinTech company in Japan that operates a digital finance platform centered on payments, offering a range of payment and financial services to users and merchants. The company has two reportable segments: i) Payment segment: It includes payment settlement services and related services through its PayPay app, and credit payment settlement services such as revolving and installment payment options and cash advances; and ii) Financial service segment: It includes internet banking services, securities intermediary services and PayPay Point investment-related services, and loan management services. The majority of revenue is derived from the Payment segment. Geographically, the company's maximum revenue is generated in Japan.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.